Composition for promoting expression of cadherin, skin care product and application

Abstract

The embodiment of the invention provides a composition for promoting cadherin expression, a skin care substance and application. The composition and the skin care substance can be used for promoting DSG1 expression. The composition with the function of promoting cadherin expression comprises teprenone, ceprenone, and ceprenone, and a compound represented by formula (1); wherein formula (1):

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of skin protection, in particular to a composition for promoting expression of desmocollin, a skin care product and use. BACKGROUND

[0002] DSG1, full name Desmoglein 1, is a kind of desmocollin, mainly expressed in the squamous epithelium of skin and mucosa, especially in the granular layer and upper spinous layer of epidermis. DSG1 plays an important role in maintaining intercellular adhesion and tissue integrity, and is involved in regulating cell proliferation, differentiation and morphogenesis. In terms of skin barrier function, DSG1 is essential to maintain the integrity of the skin barrier. The expression of DSG1 in aged skin tissue is significantly reduced, leading to loose desmosome structure, thinning of the skin, increased wrinkles.

[0003] The skin barrier is the protective layer of the outermost layer of the skin, mainly composed of the stratum corneum of the epidermis, which can prevent the invasion of harmful substances from the outside world, and also prevent the loss of water and nutrients in the body. The health of the skin barrier is essential to maintain the function of the skin. Skin epidermal functional proteins are key components of the skin barrier, including keratin, structural proteins and some intercellular junction proteins.

[0004] The skin barrier is damaged, leading to the erosion of bacteria, viruses and fungi in the skin, and also leading to the unscrupulous evaporation of water in the skin, and thus causing various problems in the skin. Therefore, protecting the integrity of the skin barrier, avoiding excessive cleaning, using irritating cosmetics and other behaviors are important measures to maintain skin health. At the same time, using skin care products containing repair ingredients can help repair and strengthen the skin barrier.

[0005] As can be seen from the above, DSG1 protein can play an important role in skin protection. Therefore, how to promote the expression of DSG1 protein is an important problem worthy of study.

[0006] Teprenone has been widely used as an anti-ulcer drug in the clinical field. In addition, there are many studies, such as Chinese patent documents with publication numbers CN113425611A (named Anti-aging composition for four-dimensional tissue repair by teprenone and its application) and CN116077367A (named Freeze-dried powder composition with skin repair function), which have disclosed that teprenone can be applied to skin care.

[0007] However, there is no relevant research on the relationship between teprenone and DSG1. That is, how to promote the expression of DSG1 by teprenone is a problem to be solved. SUMMARY

[0008] An object of embodiments of the present application is to solve at least one of the problems in the above background and provide corresponding beneficial effects.

[0009] Another object of embodiments of the present application is to provide a composition for promoting expression of cadherin, a skin care product and a use, which can be used to solve the problem of how to promote expression of DSG1 by repirinast.

[0010] Embodiments of the present application provide, in a first aspect, a composition comprising:

[0011] repirinast; and

[0012] a compound represented by formula (1); wherein,

[0013] formula (1):

[0014] The composition can achieve the effect of promoting expression of cadherin (DSG1).

[0015] In some embodiments, the mass ratio of repirinast to the compound of formula 1 is 10:(4-12).

[0016] In some embodiments, the mass ratio of repirinast to the compound of formula 1 is 10:(4.62-11.56).

[0017] In some embodiments, the concentration of repirinast is 10 μg / mL, and the concentration of the compound of formula 1 is 4-12 μg / mL, which is conducive to promoting expression of DSG1.

[0018] In some embodiments, the concentration of repirinast is 10 μg / mL, and the concentration of the compound of formula 1 is 4.62-11.56 μg / mL, which is conducive to promoting expression of DSG1.

[0019] In some embodiments, the concentration of the compound of formula 1 is 4.62 μg / mL.

[0020] In some embodiments, the concentration of the compound of formula 1 is 11.56 μg / mL.

[0021] In a second aspect, embodiments of the present application provide a skin care product comprising the composition of the first aspect.

[0022] In a third aspect, embodiments of the present application provide a use of the composition of the first aspect in the preparation of a skin care product.

[0023] In some embodiments, the skin care product is used to promote wound healing.

[0024] In some embodiments, the skin care product is used to protect the skin barrier.

[0025] In some embodiments, the skin care product is used for skin anti-aging.

[0026] In a fourth aspect, the embodiments of the present application provide a use of the compound represented by the formula (1) and / or the compound represented by the formula (1) in the preparation of a composition for promoting the expression of DSG1.

[0027] In some embodiments, the composition is used for promoting wound healing.

[0028] In some embodiments, the composition is used for protecting the skin barrier.

[0029] In some embodiments, the skin care product is used for skin anti-aging.

[0030] The beneficial effects of the embodiments of the present application include:

[0031] 1. In some embodiments, the embodiments of the present application provide a composition for promoting the expression of DSG1, which includes the compound represented by the formula (1) and the compound represented by the formula (1), and can promote the expression of DSG1 protein through the synergistic effect of the compound represented by the formula (1) and the compound represented by the formula (1), so as to overcome the defects in the background art.

[0032] 2. In some embodiments, the composition provided by the embodiments of the present application promotes the expression of DSG1 through the synergistic effect of the compound represented by the formula (1) and the compound represented by the formula (1), which is beneficial to achieve the effect of skin anti-aging and tightening.

[0033] 3. In some embodiments, the composition provided by the embodiments of the present application promotes the expression of DSG1 through the synergistic effect of the compound represented by the formula (1) and the compound represented by the formula (1), which is beneficial to achieve the effect of protecting the skin barrier.

[0034] 4. In some embodiments, the composition provided by the embodiments of the present application promotes the expression of DSG1 through the synergistic effect of the compound represented by the formula (1) and the compound represented by the formula (1), which is beneficial to achieve the effect of promoting the faster healing of skin wounds.

[0035] 5. In some embodiments, the embodiments of the present application provide a use of the composition with the DSG1 expression function in the preparation of a skin care product, which is beneficial to improve the skin protection effect of the skin care product.

[0036] 6. In some embodiments, the embodiments of the present application provide a use of the compound represented by the formula (1) in the preparation of a composition with the function of promoting the expression of DSG1, which is beneficial to improve the expression of DSG1. BRIEF DESCRIPTION OF DRAWINGS

[0037] Figure 1 FIG. 1 is a structural schematic diagram of the compound represented by the formula (1) in the embodiments of the present application;

[0038] Figure 2 A structural schematic diagram of one of the compounds of the present application is shown in Figure 1.

[0039] Figure 3 A mass spectrum diagram of the compound of the present application is shown in Figure 2.

[0040] Figure 4 A nuclear magnetic resonance hydrogen spectrum diagram of the compound of the present application is shown in Figure 3.

[0041] Figure 5 A nuclear magnetic resonance carbon spectrum diagram of the compound of the present application is shown in Figure 4.

[0042] Figure 6 A cell survival rate diagram of the present application is shown in Figure 5.

[0043] Figure 7 A mRNA relative expression level diagram of the present application is shown in Figure 6.

[0044] Figure 8 A mRNA relative expression level diagram of the present application is shown in Figure 7. DETAILED DESCRIPTION

[0045] The present application will be further described in details with reference to the accompanying drawings, so that those skilled in the art can implement the present application according to the description in the specification.

[0046] The terms "first", "second", and the like in the present application are only used for descriptive purpose, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the technical features indicated. Therefore, the features defined with "first", "second", and the like can explicitly or implicitly include at least one of the features.

[0047] Furthermore, the terms "comprise", "have" and any variations thereof are intended to cover non-exclusive inclusion. For example, a process, method, system, product or device including a series of steps or units is not limited to the listed steps or units, but can optionally include other steps or units not listed or can optionally include other steps or units inherent to the process, method, product or device.

[0048] In addition to the above, it is still emphasized that reference herein to an "embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment can be included in at least one embodiment of the application. The appearances of the phrase in various places in the specification are not necessarily all referring to the same embodiment nor are they necessarily mutually exclusive of one another. It is explicitly contemplated that embodiments described herein can be combined with other embodiments.

[0049] <Composition>

[0050] The inventors of the present application have unexpectedly found that, through real-time fluorescent quantitative PCR experiments, the specific combination of the compound of formula I and teprenone produces a synergistic effect on the gene transcription level of the regulatory factor DSG1 protein at the HaCaT cell level.

[0051] Accordingly, the embodiments of the present application provide a composition comprising:

[0052] teprenone; and

[0053] a compound represented by formula (1) (referred to as formula 1 compound) ; wherein,

[0054] Formula (1) :

[0055] The composition provided by the embodiments of the present application, comprising teprenone and the formula 1 compound, can produce a synergistic effect to promote the expression of DSG1 protein, and thus can be used to overcome the defects in the background art.

[0056] In addition, the composition provided by the embodiments of the present application can also be used to maintain the integrity and barrier function of the skin. The specific reason is that DSG1 (Desmoglein 1) is one of the members of the Desmoglein family of core proteins and is the main component of the desmosome. DSG1 is one of the key proteins that make up the desmosome, and through interaction with DSG1 and other desmosome components of adjacent cells, it forms a tight intercellular connection between keratinocytes in the skin, enabling skin cells to resist physical friction, chemical stimulation, and microbial invasion from the outside, and maintaining the integrity and barrier function of the skin.

[0057] In addition, DSG1 is also involved in the intracellular signal transduction process. When DSG1 binds to the corresponding protein of the adjacent cell, it will trigger a series of activation or inhibition of intracellular signaling pathways, thereby regulating the biological behaviors of cell proliferation, differentiation, migration, and apoptosis. For example, in the process of skin wound repair, the DSG1-mediated signaling pathway can promote the migration and proliferation of keratinocytes, accelerating the healing of the wound. Therefore, the composition of the embodiments of the present application can also promote faster wound healing by promoting the expression of DSG1 protein.

[0058] In some embodiments, the mass ratio of the Tipiracil to the compound of Formula 1 is 10:(4-12), i.e., 5:(2-6), further optionally 10:(4.62-11.56).

[0059] In some embodiments, the concentration of the Tipiracil is 10 pg / mL, and the concentration of the compound of Formula 1 is 4-12 pg / mL, which is conducive to promoting the expression of DSG1.

[0060] In some embodiments, the concentration of the Tipiracil is 10 pg / mL, and the concentration of the compound of Formula 1 is 4.62-11.56 pg / mL, which is conducive to promoting the expression of DSG1. Optionally, the concentration of the compound of Formula 1 is 4.62 pg / mL; optionally, the concentration of the compound of Formula 1 is 11.56 pg / mL.

[0061] In some embodiments, the composition comprises a solvent for dissolving the Tipiracil and the compound of Formula 1.

[0062] In some embodiments, the solvent is a cosmetically acceptable solvent, which can comprise one or more of water, p-hydroxyacetophenone, hexylene glycol, butylene glycol, and the like.

[0063] In some embodiments, the composition comprises a cosmetically acceptable adjuvant. Optionally, the adjuvant is selected from one or more of surfactants and / or emulsifiers, preservatives, buffers, chelating agents, denaturants, sunscreens, pH adjusters, reducing and stabilizing agents, thickening agents, gelling agents, film-forming polymers, fillers, matting agents, gloss agents, pigments, dyes, fragrances, and mixtures thereof.

[0064] In certain embodiments, the composition can be manufactured in the form of a cream, a liquid, a gel, a powder, a block, a solid paste, a wax-based, a lyophilized, a spray, an aerosol, or a substrate, and the like.

[0065] Optionally, the cream form is further in the form of a milk, a paste, a cream, a honey, a fat, a milk, an emulsion, a milk, or a serum, and the like.

[0066] Optionally, the liquid form is further in the form of a serum, a liquid, a water, an oil, or an oil-water separation, and the like.

[0067] Optionally, the gel form can be further in the form of a jelly or a glue, and the like.

[0068] Optionally, the powder form can be further in the form of a loose powder or a granule, and the like.

[0069] Optionally, the block form can be further in the form of a block powder, a large solid, and the like.

[0070] Optionally, the wax-based is based on wax as the main base.

[0071] Optionally, the lyophilized form is further lyophilized powder, lyophilized tablet, etc.

[0072] Optionally, the spray does not contain propellant.

[0073] Optionally, the aerosol contains propellant.

[0074] Optionally, the substrate is in the form of a patch, film, etc.

[0075] In some embodiments, the composition can be applied topically to the hair, body hair, torso, head, face, eye, lip, hand, foot, whole body skin, finger (toe), nail, etc.

[0076] In some embodiments, the composition can be used to prepare a skin care product. By promoting the expression of DSG1, the skin can be protected.

[0077] In some embodiments, the skin care product is an external skin care preparation.

[0078] In some embodiments, the composition is a skin care product, wherein the sum of the mass fraction of the compound of formula 1 and the compound of formula 1 in the composition is 0.0001-10%.

[0079] It should be noted that the compound of formula 1 can be obtained by direct purchase or synthesized by the following steps S1-S3:

[0080] Step S1, in a 50 mL round-bottom flask, add 466 mg of ferulic acid (3-methoxy-4-hydroxycinnamic acid), dissolve in 10 mL of dichloromethane, then add 1.4 mL of triethylamine, the resulting reaction solution is stirred with a magnetic stirrer, and cooled to 0-5℃ with an ice water bath, then slowly add 900 mg of tert-butyl dimethylchlorosilane, stir at room temperature for 4 hours. After the reaction is completed, quench the reaction with 25 mL of ice water, extract the water layer with dichloromethane (25 mL x 3), combine the organic layers, dry the organic layer with anhydrous sodium sulfate, filter, and vacuum concentrate to obtain the crude product. Dissolve the crude product in 20 mL of tetrahydrofuran and 2 mL of water, add 200 mg of anhydrous potassium carbonate, and stir at room temperature for 6 hours. After the reaction is completed, add 25 mL of water and extract the water layer with ethyl acetate (25 mL x 3), combine the organic layers, vacuum concentrate, and recrystallize with petroleum ether to obtain the first intermediate;

[0081] Step S2, in a 50 mL brown round bottom flask, add the first intermediate 308 mg, retinol 343 mg, EDCI 288 mg and DMAP 12 mg, add tetrahydrofuran 5 mL for dissolution, finally add TEA 270 μL, stir the reaction at room temperature for 12 hours. After the reaction is completed, the reaction liquid is concentrated under vacuum, 25 mL of water is added, the water layer is extracted with ethyl acetate (25 mL x 3), the combined organic layer is dried by adding anhydrous sodium sulfate, filtered, vacuum concentrated to obtain the crude product, and column chromatography on silica gel (petroleum ether: ethyl acetate = 20:1 as eluent) to obtain the second intermediate;

[0082] Step S3, in a 50 mL brown round bottom flask, add the second intermediate 384 mg, dissolve with tetrahydrofuran 8 mL, cool to 0-5°C with an ice water bath, slowly add tetrabutylammonium fluoride 600 μL, and stir in an ice bath for 10 minutes. Vacuum concentration to obtain the crude product, column chromatography on silica gel (petroleum ether: ethyl acetate = 5:1 as eluent) to obtain the compound of formula (I).

[0083] The mass spectrum data of the compound of formula 1 is shown in Figure 3 , the chemical formula is C 30 H 38 O4, the molecular weight is 461.26973.

[0084] The hydrogen spectrum nuclear magnetic resonance data of the compound of formula 1 is shown in Figure 4 , (P1175 in Figure 4 is the number of the compound of formula 1), and the data is as follows:

[0085] 1 H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 15.9 Hz, 1H), 7.07 (dd, J = 8.3, 2.0 Hz, 1H), 7.02 (d, J = 1.9 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.65 (dd, J = 15.1, 11.2 Hz, 1H), 6.30 (d, J = 15.9 Hz, 2H), 6.22-6.06 (m, 3H), 5.90 (s, 1H), 5.69 (t, J = 7.2 Hz, 1H), 4.86 (d, J = 7.2 Hz, 2H), 3.92 (s, 3H), 2.01 (t, J = 6.3 Hz, 2H), 1.96 (s, 3H), 1.93 (s, 3H), 1.71 (s, 3H), 1.63-1.57 (m, 2H), 1.49-1.44 (m, 2H), 1.02 (s, 6H).

[0086] The carbon spectrum nuclear magnetic resonance data of the compound of formula 1 is shown in Figure 5 , and the data is as follows:

[0087] 13 C NMR (101 MHz, CDC13) δ 167.18, 147.98, 146.76, 144.97, 139.15, 137.77, 137.55, 136.53, 135.82, 129.93, 129.30, 126.93, 125.74, 124.61, 123.05, 115.28, 114.72, 109.31, 61.20, 55.86, 39.57, 34.21, 33.02, 28.91, 21.68, 19.22, 12.75, 12.69.

[0088] The hydrogen spectrum nuclear magnetic data is measured by a nuclear magnetic resonance spectrometer (model: JNM-ECZ500R / S1, manufacturer: JEOL, Japan). The carbon spectrum nuclear magnetic data is measured by a nuclear magnetic resonance spectrometer (model: Bruker AV NEO 400, manufacturer: Bruker, USA).

[0089] It should be further noted that teprenone, also known as elipronil, is a chemical. The chemical name is 6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2-one, the molecular formula is C 23 H 38 O, and the molecular weight is 330.547. The structural formula of teprenone is shown in the following formula (2):

[0090] Formula (2):

[0091]

[0092] <Use>

[0093] It can be understood that the embodiments of the present application can also provide a use of teprenone and the compound of formula 1 in preparing a composition for promoting expression of DSG1,

[0094] Formula (1):

[0095] It can be understood that the silymarin and the compound shown in formula 1 can have a synergistic effect to promote the expression of DSG1, so that the composition for promoting the expression of DSG1 has the effect of promoting the expression of DSG1.

[0096] In some embodiments, the composition is a skin care product.

[0097] In some embodiments, the skin care product is used to promote wound healing.

[0098] In some embodiments, the skin care product is used to protect the skin barrier. In some embodiments, the skin care product is used to protect the skin barrier.

[0099] In some embodiments, the skin care product is an external skin care preparation.

[0100] In some embodiments, the mass ratio of the compound of Formula 1 to the compound of Formula 2 is 10:(4-12), i.e., 5:(2-6), and further optionally 10:(4.62-11.56).

[0101] In some embodiments, the concentration of the compound of Formula 1 is 4-12 μg / mL, and the concentration of the compound of Formula 2 is 10 μg / mL, which is conducive to promoting the expression of DSG1.

[0102] In some embodiments, the concentration of the compound of Formula 1 is 4.62-11.56 μg / mL, and the concentration of the compound of Formula 2 is 10 μg / mL, which is conducive to promoting the expression of DSG1. Optionally, the concentration of the compound of Formula 1 is 4.62 μg / mL; optionally, the concentration of the compound of Formula 1 is 11.56 μg / mL.

[0103] <Experiment>

[0104] It should be noted that in the following experimental examples 1-2, when referring to the cell culture solution, the following preparation method is referred to for preparation.

[0105] The cell culture solution is a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin, and the preparation method is as follows: fetal bovine serum (FBS), penicillin / streptomycin and DMEM medium are mixed to obtain a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin, wherein the volume fraction of FBS is 10%, and the volume fraction of penicillin / streptomycin is 1%.

[0106] DMEM (Dulbecco's Modified Eagle Medium) is a basic medium widely used in cell culture, which is rich in nutrients and maintains the pH balance of cells, and is suitable for the culture of various cell types and has a wide range of applications.

[0107] <Experimental Example 1>

[0108] Experimental samples such as sample 1-1, sample 1-2, sample 1-3, sample 1-4, sample 1-5, etc. were set up, and human immortalized keratinocytes (HaCaT) were treated with each sample, respectively. Then, the cell viability of the cells treated by each sample was detected by CCK8 method (Cell Counting Kit-8 method).

[0109] The CCK8 method can be performed according to the experimental methods described in Molecular Biology Experimental Techniques, Molecular Experimental Techniques Guide, Cell Biology Experimental Course or Biochemistry and Molecular Biology Experiments.

[0110] Specifically, the CCK8 method was performed according to the related methods described in Molecular Biology Experimental Techniques (published by Chemical Industry Press in 2008, written by Qu Sheng and Liu Zhiguo, ISBN: 9787122010285) in Experimental Example 1.

[0111] 1. Experimental samples

[0112] The experimental samples, sample 1-1, sample 1-2, sample 1-3, sample 1-4, sample 1-5, etc., are as follows.

[0113] Sample 1-1:

[0114] Sample 1-1 is a culture solution containing tiprenone, wherein the concentration of tiprenone is 10 μg / mL.

[0115] The preparation method of sample 1-1 is as follows:

[0116] Mix the cell culture solution and tiprenone to obtain sample 1-1.

[0117] Sample 1-2:

[0118] Sample 1-2 is a culture solution containing a compound of formula 1, wherein the concentration of the compound of formula 1 is 4.62 μg / mL.

[0119] The preparation method of sample 1-2 is as follows:

[0120] Mix the cell culture solution and the compound of formula 1 to obtain sample 1-2.

[0121] Sample 1-3:

[0122] Sample 1-3 is a culture solution containing a compound of formula 1, which is basically the same as sample 1-2, except that the concentration of the compound of formula 1 is different, so the preparation method can be implemented by referring to sample 1-2.

[0123] Among them, the concentration of the compound of formula 1 in sample 1-3 is 11.56 μg / mL.

[0124] Sample 1-4:

[0125] Sample 1-4 is a culture solution containing a compound of formula 1 and tiprenone, wherein the concentration of the compound of formula 1 is 4.62 μg / mL and the concentration of tiprenone is 10 μg / mL.

[0126] The preparation method of sample 1-4 is as follows: mix the cell culture solution, tiprenone and the compound of formula 1 to obtain sample 1-4.

[0127] Samples 1-5:

[0128] Samples 1-5 are culture media containing compound of formula 1 and teprenone, which are basically the same as samples 1-4, except for the concentration of compound of formula 1. Therefore, the preparation method can be carried out with reference to samples 1-4.

[0129] The concentration of compound 1 was 11.56 μg / mL, and the concentration of teprenone was 10 μg / mL.

[0130] 2. Experimental Results

[0131] Experimental results are as follows Figure 6 As shown.

[0132] according to Figure 6 It can be seen that when the concentration of compound 1 is 4–12 μg / mL and the concentration of teprenone is 10 μg / mL, the combined use of teprenone and compound 1 has virtually no adverse effects on cells.

[0133] <Experimental Example 2>

[0134] A control group (Control) and experimental groups 2-1 to 2-5 were set up. Human immortalized keratinocytes (HaCaT) were treated with samples from each group. Then, the expression level of DSG1 in human immortalized keratinocytes in each group was detected by qPCR (Quantitative Real-time Polymerase Chain Reaction), that is, the relative mRNA expression level of the DSG1 gene.

[0135] The qPCR method can be performed according to the experimental methods described in "Experimental Techniques in Molecular Biology", "Guide to Molecular Experimental Techniques", "Experimental Course in Cell Biology", or "Experiments in Biochemistry and Molecular Biology".

[0136] Specifically, in Experiment 2, the qPCR method was performed according to the relevant methods described in "Experimental Techniques in Molecular Biology" (published by Chemical Industry Press in 2008, written by Qu Shen and Liu Zhiguo, ISBN: 9787122010285).

[0137] 1. Experimental Samples

[0138] The samples in the control group (Control) and experimental groups 2-1 to 2-5 are Control sample, sample 2-1, sample 2-2, sample 2-3, sample 2-4, and sample 2-5, respectively, as detailed below.

[0139] Control sample:

[0140] Specifically, the cell culture solution (DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin).

[0141] Sample 2-1:

[0142] Sample 2-1 is a culture solution containing tipinacetate, wherein the concentration of tipinacetate is 10 μg / mL.

[0143] The preparation method of sample 2-1 is as follows: the cell culture solution and tipinacetate are mixed to obtain sample 2-1.

[0144] Sample 2-2:

[0145] Sample 2-2 is a culture solution containing the compound of formula 1, wherein the concentration of the compound of formula 1 is 4.62 μg / mL.

[0146] The preparation method of sample 2-2 is as follows: the cell culture solution and the compound of formula 1 are mixed to obtain sample 2-2.

[0147] Sample 2-3:

[0148] Sample 2-3 is a culture solution containing tipinacetate and the compound of formula 1, wherein the concentration of tipinacetate is 10 μg / mL and the concentration of the compound of formula 1 is 4.62 μg / mL.

[0149] The preparation method of sample 2-3 is as follows: the cell culture solution, tipinacetate and the compound of formula 1 are mixed to obtain sample 2-3.

[0150] Sample 2-4:

[0151] Sample 2-4 is a culture solution containing the compound of formula 1, which is basically the same as sample 2-2, except that the concentration of the compound of formula 1 is 11.56 μg / mL.

[0152] Sample 2-5:

[0153] Sample 2-5 is a culture solution containing tipinacetate and the compound of formula 1, which is basically the same as sample 2-3, except that the concentration of the compound of formula 1 is 11.56 μg / mL.

[0154] 2. Experimental results

[0155] The experimental results are shown in Table 2. Figures 7-8 .

[0156] Figure 7 Figure 1 is a schematic diagram of the mRNA relative expression level corresponding to the Control sample, sample 2-1, sample 2-2, and sample 2-3 in Example 2.

[0157] Figure 8A schematic diagram of the mRNA relative expression level corresponding to the Control sample, sample 2-1, sample 2-4, sample 2-5 in experimental example 2 is shown.

[0158] From the results in Table 2, it can be seen that the compound of formula 1 and the combination of the compound of formula 1 and the compound of formula 2 can promote the expression of DSG1. Figures 7-8 From the results in Table 2, it can be seen that the compound of formula 1 and the combination of the compound of formula 1 and the compound of formula 2 can promote the expression of DSG1.

[0159] Therefore, it can be understood that when the compound of formula 1 and the compound of formula 2 are combined to be applied to the composition, the composition can have the function of promoting the expression of DSG1.

[0160] <APPLICATION EXAMPLE>

[0161] The application further provides an emulsion in the application example.

[0162] The emulsion is a composition containing the compound of formula 1 and the compound of formula 2. The formula of the emulsion is shown in Table 1, and the preparation method comprises the following steps: heating phase A to 85°C and swelling uniformly to obtain a first heated material; heating phase B to 85°C and dissolving uniformly to obtain a second heated material; adding the first heated material to the second heated material and homogenizing for 2-3 min to obtain a first homogenized material; adding phase C to the first homogenized material and homogenizing for 1-2 min to obtain a second homogenized material; stirring the second homogenized material to cool to below 40°C, and then adding phase D and the dissolved phase E and stirring uniformly to obtain the emulsion.

[0163] Table 1, formula of the emulsion

[0164]

[0165] It can be understood that the emulsion contains the compound of formula 1 and the compound of formula 2, and thus can promote the expression of DSG1 and produce the corresponding skin care technical effect.

[0166] The above detailed description of the specific embodiments has explained the application in detail, but these do not constitute a limitation on the application. The protection scope of the application is not limited by the above embodiments, but any equivalent modifications or changes made by those skilled in the art according to the disclosed content of the application shall be included in the protection scope recited in the claims.

Claims

1. A composition that promotes cadherin expression, characterized in that, include: Teprenone; and The compound represented by formula (1); wherein, Equation (1):

2. The composition for promoting cadherin expression according to claim 1, characterized in that, The mass ratio of teprenone to the compound shown in formula (1) is 5:(2-6).

3. The composition for promoting cadherin expression according to claim 1, characterized in that, The mass ratio of teprenone to the compound shown in formula (1) is 10:(4.62 to 11.56).

4. The composition for promoting cadherin expression according to claim 1, characterized in that, The concentration of teprenone is 10 μg / mL, and the concentration of the compound shown in formula (1) is 4 to 12 μg / mL.

5. The composition for promoting cadherin expression according to claim 1, characterized in that, The concentration of teprenone was 10 μg / mL, and the concentration of the compound shown in formula (1) was 4.62–11.56 μg / mL.

6. A skin care product, characterized in that, include: The composition according to any one of claims 1 to 5.

7. Use of the composition for promoting cadherin expression according to any one of claims 1 to 5 in the preparation of skin care products.

8. The use according to claim 7, wherein, The skin care product is used to promote wound healing.

9. The use according to claim 7, wherein, The skin care products are used to protect the skin barrier.

10. Use of teprenone in the preparation of compositions that promote cadherin expression; wherein, The composition comprises teprenone and the compound shown in formula (1). Equation (1):

Images